Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed into law Dec. 29.
McDermott Will & Emery attorneys Emily Cook and Anisa Mohanty brought the provision to light in a Feb. 2 blog post.
Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed into law Dec. 29.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
